PTC Therapeutics Retains Significant Firepower for Bolt-On Deals, RBC Capital Markets Says
MT newswire2026/10/07 15:2211:22 AM EDT, 10/07/2026 (MT Newswires) -- PTC Therapeutics (PTCT) retains "substantial firepower" for more bolt-on deals to boost synergies and long-term leverage, RBC Capital Markets said in a note Wednesday. The company has consistently expressed interest in deals to acquire assets that would drive revenue growth, the brokerage said. PTC has indicated a "strong appetite" for late- or commercial-stage assets in rare metabolic and central nervous system diseases, RBC added. Among the areas for potential expansion is gene therapy for Duchenne muscular dystrophy, the investment firm said, noting that PTC's existing pipeline does not maximize the Duchenne muscular dystrophy network. RBC has a sector perform rating on PTC Therapeutics, with a price target of $85. Price: 63.59, Change: -0.11, Percent Change: -0.17
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SNT Holdings, Related Party Raise Combined Stake in SNTEnergy to 55.75% From 52.75%
Cold wave and rising fuel costs drive electricity prices in northeastern Japan and Tokyo to a four-year high
Japan's spot electricity prices surged to multi-year highs over the weekend.
Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail
Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.
Canaccord Genuity: Lowers Oklo's target price to $66
Crypto prices
More
